Cannabinoids for Treatment of Dystonia in Huntington’s Disease
Carsten Saft(St. Josef-Hospital), Klaus Seppi(Innsbruck Medical University), Charlotte Thiels(University Hospitals of the Ruhr-University of Bochum), Beatrice Heim(Innsbruck Medical University), Marina Peball(Innsbruck Medical University), Atbin Djamshidian(Innsbruck Medical University), Thomas Lücke(St. Josef-Hospital), Sarah Hein(Ruhr University Bochum)
Cited by 74
Related Papers
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy
|Movement Disorders|2022|775
The natural history of multiple system atrophy: a prospective European cohort study
|The Lancet Neurology|2013|533
Restless legs syndrome
|Neurology|2005|373
Prevalence of movement disorders in men and women aged 50–89 years (Bruneck Study cohort): a population-based study
|The Lancet Neurology|2005|301